Zacks: Brokerages Anticipate Sangamo Therapeutics Inc (NASDAQ:SGMO) Will Post Earnings of -$0.23 Per Share

Brokerages forecast that Sangamo Therapeutics Inc (NASDAQ:SGMO) will report ($0.23) earnings per share (EPS) for the current quarter, according to Zacks. Three analysts have made estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.37) and the highest estimate coming in at ($0.03). Sangamo Therapeutics posted earnings per share of ($0.26) during the same quarter last year, which would suggest a positive year-over-year growth rate of 11.5%. The company is scheduled to report its next quarterly earnings report on Wednesday, August 5th.

According to Zacks, analysts expect that Sangamo Therapeutics will report full year earnings of ($0.16) per share for the current fiscal year, with EPS estimates ranging from ($1.38) to $1.51. For the next year, analysts expect that the business will report earnings of ($1.20) per share, with EPS estimates ranging from ($1.45) to ($0.87). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Monday, May 11th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.14). The company had revenue of $13.10 million for the quarter, compared to analysts’ expectations of $22.73 million. Sangamo Therapeutics had a negative return on equity of 22.68% and a negative net margin of 89.31%. The company’s revenue for the quarter was up 61.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.41) EPS.

A number of brokerages have issued reports on SGMO. ValuEngine lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, June 1st. HC Wainwright decreased their price target on Sangamo Therapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, June 22nd. Zacks Investment Research lowered Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. BidaskClub lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, June 5th. Finally, Wedbush reissued a “hold” rating and issued a $11.00 price target on shares of Sangamo Therapeutics in a research note on Friday, June 19th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $11.50.

NASDAQ:SGMO traded up $0.04 during mid-day trading on Tuesday, reaching $8.77. The company’s stock had a trading volume of 1,634,000 shares, compared to its average volume of 2,356,573. The company’s fifty day simple moving average is $10.47 and its two-hundred day simple moving average is $8.39. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.98 and a quick ratio of 5.98. Sangamo Therapeutics has a twelve month low of $4.81 and a twelve month high of $13.33. The stock has a market cap of $1.23 billion, a P/E ratio of -10.57 and a beta of 2.25.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Great West Life Assurance Co. Can acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $65,000. Cannell Peter B & Co. Inc. acquired a new position in shares of Sangamo Therapeutics in the 1st quarter valued at about $65,000. Bedel Financial Consulting Inc. lifted its stake in shares of Sangamo Therapeutics by 1,538.5% in the 1st quarter. Bedel Financial Consulting Inc. now owns 10,650 shares of the biopharmaceutical company’s stock valued at $68,000 after purchasing an additional 10,000 shares in the last quarter. Norges Bank acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $84,000. Finally, AlphaCrest Capital Management LLC acquired a new position in shares of Sangamo Therapeutics in the 4th quarter valued at about $85,000. 52.92% of the stock is currently owned by institutional investors and hedge funds.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.

See Also: Holder of Record

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.